Tyrosine kinase inhibitors (TKIs), specifically inhibiting BCR-ABL fusion protein and triggering apoptosis and differentiation of CML cells, are used as first-line treatment for CML [2]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.